Kava: a comprehensive review of efficacy, safety, and psychopharmacology (Q33745578)

29 July 2017

Kava: a comprehensive review of efficacy, safety, and psychopharmacology (English)

1 reference

29 July 2017

Jerome Sarris

1

1 reference

PubMed ID

21073405

29 July 2017

Emma LaPorte

series ordinal

2

1 reference

PubMed ID

21073405

29 July 2017

Isaac Schweitzer

series ordinal

3

1 reference

29 July 2017

15 November 2010

1 reference

Australian and New Zealand Journal of Psychiatry

29 July 2017

1 reference

29 July 2017

45

1 reference

29 July 2017

27-35

1 reference

29 July 2017

1

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

29 July 2017

1 reference

A systematic review of the safety of kava extract in the treatment of anxiety

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

Kava-kava and anxiety: growing knowledge about the efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

Kava kava: examining new reports of toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

The neurobehavioural effects of kava.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

Anesthetic considerations of the herbal, kava

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

Therapeutic potential of kava in the treatment of anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

In vitro toxicity of kava alkaloid, pipermethystine, in HepG2 cells compared to kavalactones

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

The protective action of tetrodotoxin and (+/-)-kavain on anaerobic glycolysis, ATP content and intracellular Na+ and Ca2+ of anoxic brain vesicles.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

The antinociceptive actions of kava components in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

Antithrombotic action of the kava pyrone (+)-kavain prepared from Piper methysticum on human platelets.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

Stress-induced insomnia treated with kava and valerian: singly and in combination

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

Kava pyrones and resin: studies on GABAA, GABAB and benzodiazepine binding sites in rodent brain

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

Influence of genuine kavapyrone enantiomers on the GABA-A binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

Meta-analysis of the efficacy of the acetonic kava-kava extract WS1490 in patients with non-psychotic anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

A placebo-controlled study of Kava kava in generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

Kava treatment in patients with anxiety.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

Kava-kava extract WS 1490 versus placebo in anxiety disorders--a randomized placebo-controlled 25-week outpatient trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

Efficacy of a special Kava extract (Piper methysticum) in patients with states of anxiety, tension and excitedness of non-mental origin - A double-blind placebo-controlled study of four weeks treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

Kava-Kava administration reduces anxiety in perimenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

Pharmacogenetics and psychopharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

Potential for interaction of kava and St. John's wort with drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

Kava lactones and the kava-kava controversy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

Kava hepatotoxicity: comparison of aqueous, ethanolic, acetonic kava extracts and kava-herbs mixtures.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

Inhibition of human cytochrome P450 activities by kava extract and kavalactones

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

Pharmacokinetics and disposition of the kavalactone kawain: interaction with kava extract and kavalactones in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

Coma from the health food store: interaction between kava and alprazolam

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

Health effects of kava use in an eastern Arnhem Land Aboriginal community

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

Enough! or too much. What is ‘excessive’ kava use in Arnhem Land?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

Enhanced cognitive performance and cheerful mood by standardized extracts of Piper methysticum (Kava-kava).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

Effects of oxazepam and an extract of kava roots (Piper methysticum) on event-related potentials in a word recognition task.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

Acute effects of kava on measures of cognitive performance, physiological function and mood.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

Saccade and cognitive function in chronic kava users.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

Saccade and cognitive impairment associated with kava intoxication.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

Evidence-based pharmacotherapy of Generalized Anxiety Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

Sexual side-effects of contemporary antidepressants: review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

The role of pharmacogenetics in the treatment of depression and anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

New perspectives for synergy research with the "omic"-technologies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

(+/-)-Kavain inhibits veratridine-activated voltage-dependent Na(+)-channels in synaptosomes prepared from rat cerebral cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

Kava extract ingredients, (+)-methysticin and (+/-)-kavain inhibit voltage-operated Na(+)-channels in rat CA1 hippocampal neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

[3H]-monoamine uptake inhibition properties of kava pyrones

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

Kavalactones and dihydrokavain modulate GABAergic activity in a rat gastric-brainstem preparation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

Inhibition of platelet MAO-B by kava pyrone-enriched extract from Piper methysticum Forster (kava-kava)

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2010.522554

10.3109/00048674.2010.522554

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

21073405